- Home
- DJCO vs TRML Comparison
DJCO vs TRML Comparison
Compare DJCO & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJCO
- TRML
- Stock Information
- Founded
- DJCO 1987
- TRML 2021
- Country
- DJCO United States
- TRML United States
- Employees
- DJCO N/A
- TRML N/A
- Industry
- DJCO Newspapers/Magazines
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- DJCO Consumer Discretionary
- TRML Health Care
- Exchange
- DJCO Nasdaq
- TRML Nasdaq
- Market Cap
- DJCO 571.5M
- TRML 598.9M
- IPO Year
- DJCO N/A
- TRML N/A
- Fundamental
- Price
- DJCO $445.87
- TRML $47.65
- Analyst Decision
- DJCO
- TRML Hold
- Analyst Count
- DJCO 0
- TRML 12
- Target Price
- DJCO N/A
- TRML $47.04
- AVG Volume (30 Days)
- DJCO 62.2K
- TRML 1.6M
- Earning Date
- DJCO 08-14-2025
- TRML 11-06-2025
- Dividend Yield
- DJCO N/A
- TRML N/A
- EPS Growth
- DJCO 115.36
- TRML N/A
- EPS
- DJCO 70.22
- TRML N/A
- Revenue
- DJCO $79,159,000.00
- TRML N/A
- Revenue This Year
- DJCO N/A
- TRML N/A
- Revenue Next Year
- DJCO N/A
- TRML N/A
- P/E Ratio
- DJCO $5.81
- TRML N/A
- Revenue Growth
- DJCO 10.54
- TRML N/A
- 52 Week Low
- DJCO $359.34
- TRML $11.56
- 52 Week High
- DJCO $602.00
- TRML $47.70
- Technical
- Relative Strength Index (RSI)
- DJCO 48.28
- TRML 94.40
- Support Level
- DJCO $406.77
- TRML $22.31
- Resistance Level
- DJCO $502.30
- TRML $47.69
- Average True Range (ATR)
- DJCO 18.06
- TRML 1.15
- MACD
- DJCO -6.68
- TRML 2.54
- Stochastic Oscillator
- DJCO 40.93
- TRML 99.80
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.